UNSPSC 51372203: Levomoramide

This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M86YFN15D, chemically known as pyrrolidine, 1-(3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)-, (s)- but generally known as levomoramide, which bears US NIH Compound Identifier 9648. European Medicines Agency schedules Levomoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08481MIG.

UNSPSC 51372203 Levomoramide is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent solicitations tagged under this code actually span a broader range of medications and health-supply procurement rather than levomoramide specifically. State and local governments buy generic multi-source pharmaceuticals, over-the-counter products, naloxone, drug deactivation systems, and direct-to-manufacturer prescription fulfillment services under this classification. Issuing bodies include state health and human services departments, county health agencies, and cooperative purchasing alliances administering multi-state pharmaceutical procurement programs. The mix reflects both individual county-level health initiatives and statewide coordinated purchasing vehicles designed to aggregate demand across multiple jurisdictions and wholesalers.

Recent activity centers on Minnesota, Florida, and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness scheduled for July 1, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and comply with cGMP and Drug Supply Chain Security Act requirements. Seminole County, Florida released an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative outside traditional pharmacy benefit manager arrangements. These solicitations indicate active state-level pharmaceutical procurement through cooperative vehicles and growing county-level demand for opioid-response medications and harm-reduction supplies.